Dubai Final-v20.indd - World Allergy Organization

More documents

Recommendations

Info

ABstrACts ABstrACts ragweed, dust mites, grasses, and/or trees. subjects were asked to rate their ocular itching on a scale of 0 to 4 in increments of 0.5, with 0 = none and 4 = severe. All subjects were required to have zero itching bilaterally (both scores = 0) at baseline. this analysis focused on a subset of 40 subjects who were dosed in one eye with olopatadine 0.2% and in the contralateral eye with placebo. Eligible subjects were challenged with antigen at 27 minutes after dosing with drug or placebo. this post hoc efficacy analysis evaluated the ability of the drug to reduce itching scores to zero.. the safety analysis was based on an evaluation of the exposure to study drug, adverse events, visual acuity, ocular signs, and fundus parameters. results: the 40 subjects had an average age of 39 ± 11 years; 65% were women and 35% were men. At 3 minutes after the antigen challenge, 63% of subjects (25 of 40) reported having zero itching in their olopatadine-treated eyes, while only 3% of subjects (1 of 40) reported having zero itching in their placebo-treated eyes. At 5 minutes after the antigen challenge, 63% of subjects (25 of 40) reported having zero itching in their olopatadine-treated eyes, while only 5% of subjects (2 of 40) reported zero itch in their placebo-treated eyes. At 7 minutes after the antigen challenge, 65% of subjects (26 of 40) reported zero itch in their olopatadine-treated eyes, while only 10% of subjects (4 of 40) reported zero itch in their placebo-treated eyes. the percentages of eyes with zero itch scores were significantly higher in the olopatadine group than in the placebo group at every time point (p < 0.05). no treatment-related adverse events were reported during the study. Conclusion: in this placebo-controlled, contralateral-designed, double-masked conjunctival antigen challenge study, olopatadine HCl ophthalmic solution 0.2% prevented any allergen-induced ocular itching response in a majority of eyes. the percentages of eyes with zero itch scores were significantly higher in the olopatadine group than in the placebo group at every analysis time point. 1409 momETaSonE FUroaTE naSal SPraY inCrEaSES THE nUmBEr oF DaYS WiTH minimal SYmPTomS in PaTiEnTS WiTH aCUTE rHinoSinUSiTiS Danzig, m. 1 , meltzer, E. O. 2 , gates, D. 1 and gopalan, g. 3 1 2 schering-Plough research institute (now merck research laboratories), Kenilworth, nJ. <strong>Allergy</strong> and Asthma medical group & research Center, san Diego, CA. 3merck & Co., Kenilworth, nJ. Background: Acute rhinosinusitis is a potentially serious inflammatory disease triggered by viral or, rarely, bacterial infections, causing symptoms for up to 4 weeks. We studied therapeutic effects of mometasone furoate nasal spray (mFns) vs amoxicillin and placebo on increasing number of minimal symptom days. methods: Double-blind, parallel-group, placebo- and active-controlled 15-day study randomized subjects ≥12 old to mFns 200 mcg QD, mFns 200 mcg BiD, amoxicillin 500 mg tiD, or placebo. subjects maintained daily symptom diaries. Qualified subjects had major rhinosinusitis symptom score (sum of rhinorrhea, postnasal drip, congestion, sinus headache, facial pain) ≥5 and ≤12 (maximum score, 15) for ≥7 but
ABstrACts nasal Olopatadine led to more significant resolution of the postnasal-drip syndrome due to the possible synergistic effect of the combination drug regimen. 1411 USEFUlnESS oF PEaK EXPiraTorY FloW raTE aSSESSmEnT in THE SCrEEning For BronCHial HYPEr rESPonSiVEnESS in CHilDrEn WiTH allErgiC rHiniTiS nagaraju, m. K. , r, iii, m. , n, s. and r, g. Pediatric allergy and immunology, Kanchi Kamakoti CHilDs trust Hospital, Chennai, india. Background: the unified airway hypothesis explains the sequence in onset of atopic march from Allergic rhinitis(Ar) to bronchial hyper responsiveness (BHr) and subsequently to asthma in most of the children with Ar. BHr better identified with Peak expiratory flow rate (PEFr) assessment . aim identifying BHr in children with Ar with PEFr and to determine the effect of treatment of Ar on BHr. methodology : study design :Prospective observational study study Period : October 2007 – september 2008 setting : <strong>Allergy</strong> clinic Kanchi Kamakoti CHilDs trust Hospital inclusion criteria : children > 5 yrs fulfilling Allergic rhinitis and its impact on Asthma (AriA) criteria were included in the study and classified as A.mild intermittent B.mild Persistant C.severe intermittent D.severe persistant. Exclusion Ceriteria : Children aged < 5 yrs and Unable to perform PEFr sample size : 82 was arrived with confidence interval of 95% Prevalence of 10% based on previous studies method: same Postgraduate will confirm the inclusion ,exclusion Criteria. Detailed history ,complete examination and investigations (ig E levels ,Absolute eosinophil count and PEFr will be done after obtaining informed consent. treatment (oral Antihistamines and or inhaled nasal steroids ) as per AriA CritEriA for various subgroups . Follow up done. results: total 85 children were included and 58.8% were males and majority were in 6-9 yrs age group. mild intermittent ,mild Persistant ,severe intermittent, severe persistant Allergic rhinitis were observed in 48,28,5,4 children respectively.As severity increases PEFr declined (P
Page 1 and 2:
Final Program 5-8 December 2010 •
Page 3 and 4:
CO COImportant Dates 30 June 2011 E
Page 5 and 6:
WAO IntErnAtIOnAl ScIEntIfIc cOnfEr
Page 7 and 8:
ABOUt WAO the World Allergy Organiz
Page 9:
WAO mEmBEr sOCiEtiEs Albanian socie
Page 12 and 13:
gEnErAl inFOrmAtiOn, A-Z BAnKs/Atm
Page 14 and 15:
ONBREZ ® BREEZHALER ® Important n
Page 16 and 17:
COnFErEnCE inFOrmAtiOn, A-Z DisClAi
Page 18 and 19:
COnFErEnCE inFOrmAtiOn, A-Z sPEAKEr
Page 20 and 21:
Helping to control asthma throughou
Page 22 and 23:
OPtiOnAl tOUrs CitY OF COntrAsts -
Page 24 and 25:
EXHiBitiOn FlOOrPlAn sHEiKH rAsHiD
Page 26 and 27:
EXHiBitOr DirECtOrY EaaCi - Europea
Page 28:
EXHiBitOr DirECtOrY omron Healthcar
Page 32 and 33:
WAO IntErnAtIOnAl ScIEntIfIc cOnfEr
Page 34 and 35:
PrOgrAm-At-A-glAnCE registration Ou
Page 36 and 37:
sUnDAY, 5 DECEmBEr 2010 WAO IntErnA
Page 38 and 39:
sUnDAY, 5 DECEmBEr 2010 WAO IntErnA
Page 40 and 41:
mOnDAY, 6 DECEmBEr 2010 WAO IntErnA
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
tUEsDAY, 7 DECEmBEr 2010 WAO IntErn
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
WEDnEsDAY, 8 DECEmBEr 2010 WAO IntE
Page 54 and 55:
WEDnEsDAY, 8 DECEmBEr 2010 WAO IntE
Page 56 and 57:
POstErs POstErs WAO IntErnAtIOnAl S
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69: POstErs POstErs WAO IntErnAtIOnAl S
Page 78: POstErs POstErs WAO IntErnAtIOnAl S
Page 81 and 82: ABstrACts results: the prevalence o
Page 83 and 84: ABstrACts effective diagnosis and e
Page 85 and 86: ABstrACts mWCnts on OVA-asthma mode
Page 87 and 88: ABstrACts allergy in human. A Burka
Page 89 and 90: ABstrACts Patients with all negativ
Page 91 and 92: ABstrACts both gender, suggesting a
Page 93 and 94: ABstrACts 1208 THE rolE oF inTErlEU
Page 95 and 96: ABstrACts of oral steroids in last
Page 97 and 98: ABstrACts 1215 aSTHma ComPliCaTion
Page 99 and 100: ABstrACts to allergens, lower sever
Page 101 and 102: ABstrACts 1301 non-EoSinoPHiliC aST
Page 103 and 104: ABstrACts participated in this stud
Page 105 and 106: ABstrACts for attacks of shortness
Page 107 and 108: ABstrACts blood CD4+ t cells expres
Page 109 and 110: ABstrACts Conclusion Air pollution
Page 111 and 112: ABstrACts 1322 EPiTHElial CEll DEri
Page 113 and 114: ABstrACts 1326 analYSiS oF gEnE EXP
Page 115 and 116: ABstrACts rhinitis patients in Hosp
Page 117: ABstrACts selected adults from the
Page 121 and 122: ABstrACts therapy. However, patient
Page 123 and 124: ABstrACts that when Ds within the s
Page 125 and 126: ABstrACts result the patient was di
Page 127 and 128: ABstrACts 2203 FooD allErgY anD aTo
Page 129 and 130: ABstrACts 1.11+/- 0.81 for type i a
Page 131 and 132: ABstrACts 2212 aSSESSing PoTEnTial
Page 133 and 134: ABstrACts regular treatment with be
Page 135 and 136: ABstrACts 2301 EFFECT oF a SYnBioTi
Page 137 and 138: ABstrACts C3 (50 mg/dl; normal 90 -
Page 139 and 140: ABstrACts introduction : HAE is a g
Page 141 and 142: ABstrACts PoSTEr SESSion 3-1: immun
Page 143 and 144: ABstrACts smaller than 100 nm. Cell
Page 145 and 146: ABstrACts and dry weather city of A
Page 147 and 148: ABstrACts 3114 igg4 aS THE PrEDomin
Page 149 and 150: ABstrACts Conclusion: Our study dem
Page 151 and 152: ABstrACts abscesses are visible at
Page 153 and 154: ABstrACts allergen release (depot e
Page 155 and 156: ABstrACts COnClUsiOns: Empiric trea
Page 157 and 158: ABstrACts Conclusion:sPlAD and FPig
Page 159 and 160: ABstrACts autumn only in 13% of cas
Page 161 and 162: ABstrACts mEtHODs: ninety-six child
Page 163 and 164: ABstrACts 3321 aSSoCiaTion BETWEEn
Page 165 and 166: sPEAKEr AnD CHAirPErsOn inDEX last
Page 167 and 168: POstEr AUtHOr inDEX WAO IntErnAtIOn
Page 169 and 170:
POstEr AUtHOr inDEX WAO IntErnAtIOn
Page 171 and 172:
POstEr AUtHOr inDEX WAO IntErnAtIOn
Page 173 and 174:
nOtEs WAO IntErnAtIOnAl ScIEntIfIc
Page 175 and 176:
Q411-10 Allergic disease is a growi
Page 177:
2010 WAO IntErnAtIOnAl ScIEntIfIc c
show all

Dubai Final-v20.indd - World Allergy Organization

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?